FDA Publishes Draft Guidance on Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act

Summary

The US Food and Drug Administration (FDA) has released a draft guidance document outlining its approach to postmarket surveillance, aiming to increase transparency and improve the tracking of postmarket surveillance orders, with the goal of completing studies in a timely manner.